Intuitive Surgical, Inc (ISRG) Q3 2026 Earnings Call Transcript
Intuitive Surgical (ISRG) reported Q3 2026 earnings, highlighting 15% total procedure growth, with 14% in da Vinci and 31% in Ion procedures. U.S. da Vinci growth was 10%, while international growth was 20%. The company installed over 13,200 da Vinci and Ion systems worldwide. Revenue growth was driven by strong demand for da Vinci 5 and SP platforms, with 28% increase in system placements. The company also announced plans for a new manufacturing facility in Malaysia.
How this was made
The 30-second read
Why it matters
The earnings call provides the first public quantitative update on Q3 performance, offering fresh data for valuation models.
Market read
First‑report earnings data with strong procedural growth, likely to influence ISRG price action and sector sentiment.
What to watch
Potential supply‑chain constraints and reimbursement risks in emerging markets.
Background
Intuitive Surgical provides the da Vinci surgical robotics platform and recently expanded its Ion lung‑cancer treatment system.
Ticker impact
Q3 2026 earnings call disclosed a 15% increase in total procedures and 14% growth in da Vinci procedures, indicating strong demand.
potential upside as investors price in higher demand and system installations
The disclosed growth metrics are new and material, suggesting better-than-expected performance.
Market effects
Robotics and medical device sector may see broader optimism from Intuitive's growth.
Positive impact on U.S. and international healthcare technology markets.
Highlights continued global adoption of surgical robotics.
Counterpoint
If procedure growth plateaus, the stock may be overvalued despite short‑term gains.
Key entities
- CompanyIntuitive Surgical, Inc.
Manufacturer of da Vinci surgical robots.
